06 October 2020: Articles
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review
Unusual clinical course
Yanhua Yue * , Wei Wei * , Yanting Guo B , Fei Wang C , Weimin Dong D , Yue Liu B , Yan Lin G , Yang Cao G , Weiying Gu A*DOI: 10.12659/AJCR.925151
Am J Case Rep 2020; 21:e925151
Table 1. Characteristics of patients with MF and CML with coexisting JAK2 gene mutations and BCR-ABL1 translocations since 2005.
| Age (years) | Sex | Diagnosis (+CML) | Treatment | Course | Phase | Clone interaction | Reference number |
|---|---|---|---|---|---|---|---|
| 50 | M | MF | HU then I | CML, MF 4 years later | CP | BCR-ABL disappeared, JAK2 constant | []2 |
| 66 | M | MF | I then HU | Concomitant | CP? | ? | []3 |
| 55 | M | MF | I | CML, MF 2 years later | AP | BCR-ABL decreased, JAK2 increased | []4 |
| 49 | M | MF | I then D | CML, MF 2 years later | CP | BCR-ABL and JAK2 decreased | []5 |
| 64 | M | MF | I then N | Concomitant | AP | BCR-ABL decreased, JAK2 constant | []5 |
| 52 | F | MF | HU then I | Concomitant | CP | BCR-ABL and JAK2 decreased | []6 |
| 58 | M | MF | I then HU | MF, CML 4 years later | ? | BCR-ABL decreased, JAK2 increased | []7 |
| 67 | M | MF | I then HU | Concomitant | CP | ? | []8 |
| 58 | F | MF | HU, INF | Concomitant | CP? | ? | []9 |
| 67 | M | MF | N then D | MF, CML 3 years later | CP | BCR-ABL decreased, JAK2 constant | []10 |
| 58 | M | MF | HU, D | Concomitant | ? | ? | []11 |
| 75 | M | MF | I then HU | Concomitant | CP? | ? | []12 |
| 54 | F | MF | I\N\D | Concomitant | CP | BCR-ABL decreased, JAK2 constant | []13 |
| 56 | M | PV/MF | HU then R | PV/MF, CML? 16.1 years later | []14 | ||
| 73 | F | ET/MF | HU then R | ET/MF, CML? 9.6 years later | BCR-ABL and JAK2 decreased | []14 | |
| 44 | F | PV/MF | INF, R then I | PV/MF, CML 5.0 years later | []14 | ||
| 40 | F | ET/MF | R, I then B | ET/MF, CML 33 years later | CP | []14 | |
| 76 | F | ET/MF | A, I, P, R, Ara-c | ET/MF, CML 10 years later | CP-AP-BP | []14 | |
| 48 | F | MF | N, HU, R | PMF, CML 10.75 years later | CP | BCR-ABL and JAK2 decreased | []15 |
| 66 | F | ET/MF | HU, R, I, B | ET/MF, CML 3.75 years later | CP | []15 | |
| 48 | F | PV/MF | Phleb, HU, INF, I, R | PV/MF, CML 4.83 years later | CP | []15 | |
| 60 | F | PV/MF | HU, Th, R, I | PV/MF, CML 8.9 years later | []15 | ||
| 70 | M | MF | I, N, D, HU | Concomitant | BCR-ABL increased, JAK2 decreased | []15 | |
| 50 | F | MF | IA/D | Concomitant | BP | BCR-ABL and JAK2 decreased | Our case |
| A – anagrelide; AP – accelerated phase; Ara-c – cytarabine; B – bosutinib; BP – blast phase; CML – chronic myelogenous leukemia; CP – chronic phase; D – dasatinib; ET/MF – myelofibrosis secondary to essential thrombocytosis; F – Female; HU – hydroxyurea; I – imatinib; INF – interferon; IA – idarubicin and cytarabine; M – Male; MF – myelofibrosis; N – nilotinib; PV/MF – myelofibrosis secondary to polycythemia vera; P – ponatinib; Phleb – therapeutic phlebotomy; R – ruxolitinib; Th – thalidomide. | |||||||